New research shows HAND2 gene methylation may have potential as a biomarker for early endometrial cancer detection and as a predictor of treatment response.
An intrauterine device (IUD) is an effective tool in the treatment of early-stage endometrial cancer in certain patients, according to the results of a small study presented at the International Gynecological Cancer Society’s 14th biennial meeting.
A review comparing laparoscopic hysterectomy versus abdominal hysterectomy for early-stage endometrial cancer has found that rates of overall survival and disease-free survival are similar for the surgical procedures.
Researchers in France have developed a nomogram based on pathological hysterectomy characteristics to predict lymph node metastasis in patients with endometrial cancer.
Obesity does not impact perioperative outcomes in women undergoing robotic hysterectomy, according to a recent study.
Laparoscopy has short-term advantages and seemingly equivalent long-term outcomes as compared with laparotomy for endometrial cancer according to a meta-analysis of randomized controlled trials.
Laparoscopic staging of uterine cancer is associated with only a small increased risk of recurrence, according to a new study in the Journal of Clinical Oncology.
Based on the protective effects of intrauterine devices against endometrial cancer, researchers hypothesized that IUDs may also have a protective effect against cervical cancer. However, results from epidemiological and clinical studies to date have been inconclusive.
Endometrial cancer remains the most commonly diagnosed gynecologic cancer in the United States. In fact, the number of women affected by the disease continues to rise despite a slight decline in annual incidence rates in the past 30 years.
Patients with high-risk endometrial cancer, who are under the care of gynecologic oncologists, have improved survival rates, according to a study published online Jan. 24 in the Journal of Clinical Oncology.